Drug Trial Radar · NCT06662539
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
493
Actual
Start
Dec 9, 2024
Primary completion
Sep 30, 2025
Study completion Mar 7, 2026
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
Conditions
- Obesity
Interventions
PetrelintideDrug
Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
PlaceboDrug
Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in body weight to Week 28Time frame: From Baseline (Day 1) to Week 28
Locations
32 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Excel Medical Clinical Trials, LLC
Boca Raton, Florida
Innovative Research of West Florida, Inc.
Clearwater, Florida
Century Research LLC
Miami, Florida
Clinical Research Center of Florida
Pompano Beach, Florida
Palm Beach Research Center
West Palm Beach, Florida
Great Lakes Clinical Trials LLC dba Flourish Research
Chicago, Illinois
AMR Wichita East
Wichita, Kansas
Alliance For Multispecialty Research, LLC
Lexington, Kentucky
Mercury Street Medical Group, PLLC
Butte, Montana
CHEAR Center LLC
The Bronx, New York
Javara Inc
Charlotte, North Carolina
PharmQuest Life Sciences, LLC
Greensboro, North Carolina
Lucas Research, Inc.
New Bern, North Carolina
AMR Norman
Norman, Oklahoma
Altoona Center for Clinical Research - Research
Duncansville, Pennsylvania
Alliance for Multispecialty Research
Knoxville, Tennessee
Clinical Trials of Texas, LLC., dba Flourish Research
San Antonio, Texas
Manaasas Clinical Research Center
Manassas, Virginia
Krakowskie Centrum MedyczneSp.z o.o
Krakow, Lesser Poland Voivodeship, Poland
ETG Siedlce
Siedlce, Masovian Voivodeship, Poland
FutureMeds Warszawa Centrum
Warsaw, Masovian Voivodeship, Poland
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji
Warsaw, Masovian Voivodeship, Poland
ETG Warszawa
Warsaw, Masovian Voivodeship, Poland
FutureMeds Targowek
Warsaw, Masovian Voivodeship, Poland
Futuremeds Olsztyn
Olsztyn, Warmian-Masurian Voivodeship, Poland
Institutul National de Endocrinologie C I Parhon
Bucharest, Romania
Institutul Clinic Fundeni
Bucharest, Romania
Fundatia Dr Victor Babes
Bucharest, Romania
Institutul De Pneumoftiziologie Marius Nasta
Bucharest, Romania
Spitalul Clinic Judetean de Urgenta Sf Apostol Andrei Constanta
Constanța, Romania
Top Diabet
Craiova, Dolj, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.